JYP0061
/ Guangzhou JOYO Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 20, 2025
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=120 | Enrolling by invitation | Sponsor: Guangzhou JOYO Pharma Co., Ltd | Trial completion date: Feb 2025 ➔ Oct 2026 | Trial primary completion date: Feb 2025 ➔ Feb 2026
Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
November 18, 2024
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=120 | Enrolling by invitation | Sponsor: Guangzhou JOYO Pharma Co., Ltd | Not yet recruiting ➔ Enrolling by invitation
Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
November 20, 2024
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
(clinicaltrials.gov)
- P2 | N=35 | Recruiting | Sponsor: Guangzhou JOYO Pharma Co., Ltd
New P2 trial • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
December 06, 2023
A Study to Evaluate JYP0061 in Patients With Moderate-to-severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Guangzhou JOYO Pharma Co., Ltd
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
1 to 4
Of
4
Go to page
1